NZ731954A - Non-human animals having a humanized cluster of differentiation 274 gene - Google Patents
Non-human animals having a humanized cluster of differentiation 274 geneInfo
- Publication number
- NZ731954A NZ731954A NZ731954A NZ73195415A NZ731954A NZ 731954 A NZ731954 A NZ 731954A NZ 731954 A NZ731954 A NZ 731954A NZ 73195415 A NZ73195415 A NZ 73195415A NZ 731954 A NZ731954 A NZ 731954A
- Authority
- NZ
- New Zealand
- Prior art keywords
- gene
- differentiation
- rodents
- polypeptide
- human animals
- Prior art date
Links
- 230000004069 differentiation Effects 0.000 title abstract 2
- 108090000623 proteins and genes Proteins 0.000 title abstract 2
- 241001465754 Metazoa Species 0.000 title 1
- 241000283984 Rodentia Species 0.000 abstract 5
- 229920001184 polypeptide Polymers 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 2
- 101150091609 CD274 gene Proteins 0.000 abstract 1
- 101100407305 Homo sapiens CD274 gene Proteins 0.000 abstract 1
- 101001117317 Homo sapiens Programmed cell death 1 ligand 1 Proteins 0.000 abstract 1
- 238000003782 apoptosis assay Methods 0.000 abstract 1
- 238000012239 gene modification Methods 0.000 abstract 1
- 230000005017 genetic modification Effects 0.000 abstract 1
- 235000013617 genetically modified food Nutrition 0.000 abstract 1
- 102000048776 human CD274 Human genes 0.000 abstract 1
- 230000003834 intracellular effect Effects 0.000 abstract 1
- 239000003446 ligand Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000005522 programmed cell death Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
- A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2207/00—Modified animals
- A01K2207/15—Humanized animals
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/15—Animals comprising multiple alterations of the genome, by transgenesis or homologous recombination, e.g. obtained by cross-breeding
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/02—Animal zootechnically ameliorated
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0331—Animal model for proliferative diseases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Environmental Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Public Health (AREA)
- Biotechnology (AREA)
- Animal Husbandry (AREA)
- Biodiversity & Conservation Biology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Pathology (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NZ770783A NZ770783A (en) | 2014-12-09 | 2015-12-09 | Non-human animals having a humanized cluster of differentiation 274 gene |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462089549P | 2014-12-09 | 2014-12-09 | |
| US201562106525P | 2015-01-22 | 2015-01-22 | |
| PCT/US2015/064626 WO2016094481A1 (en) | 2014-12-09 | 2015-12-09 | Non-human animals having a humanized cluster of differentiation 274 gene |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ731954A true NZ731954A (en) | 2024-11-29 |
Family
ID=55024286
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ731954A NZ731954A (en) | 2014-12-09 | 2015-12-09 | Non-human animals having a humanized cluster of differentiation 274 gene |
| NZ770783A NZ770783A (en) | 2014-12-09 | 2015-12-09 | Non-human animals having a humanized cluster of differentiation 274 gene |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ770783A NZ770783A (en) | 2014-12-09 | 2015-12-09 | Non-human animals having a humanized cluster of differentiation 274 gene |
Country Status (27)
| Country | Link |
|---|---|
| US (4) | US9913461B2 (enExample) |
| EP (3) | EP3808775B1 (enExample) |
| JP (3) | JP2018500896A (enExample) |
| KR (2) | KR102316842B1 (enExample) |
| CN (2) | CN107257624B (enExample) |
| AU (3) | AU2015360667B2 (enExample) |
| BR (1) | BR112017011982A2 (enExample) |
| CA (1) | CA2968675C (enExample) |
| CY (1) | CY1123723T1 (enExample) |
| DK (2) | DK3230320T3 (enExample) |
| ES (2) | ES2982515T3 (enExample) |
| FI (1) | FI3808775T3 (enExample) |
| HR (2) | HRP20240855T1 (enExample) |
| HU (2) | HUE052606T2 (enExample) |
| IL (3) | IL282649B (enExample) |
| LT (2) | LT3230320T (enExample) |
| MX (1) | MX2017007636A (enExample) |
| NZ (2) | NZ731954A (enExample) |
| PL (1) | PL3808775T3 (enExample) |
| PT (2) | PT3230320T (enExample) |
| RS (2) | RS65664B1 (enExample) |
| RU (1) | RU2711729C2 (enExample) |
| SG (2) | SG11201703931QA (enExample) |
| SI (2) | SI3808775T1 (enExample) |
| SM (2) | SMT202400313T1 (enExample) |
| WO (1) | WO2016094481A1 (enExample) |
| ZA (1) | ZA201703263B (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LT3230320T (lt) * | 2014-12-09 | 2021-01-11 | Regeneron Pharmaceuticals, Inc. | Gyvūnai, išskyrus žmogų, turintys humanizuotą diferenciacijos klasterio 274 geną |
| WO2017087780A1 (en) | 2015-11-20 | 2017-05-26 | Regeneron Pharmaceuticals, Inc. | Non-human animals having a humanized lymphocyte-activation gene 3 |
| CN108779159B (zh) | 2016-02-04 | 2022-12-30 | 瑞泽恩制药公司 | 具有经改造的angptl8基因的非人动物 |
| WO2017151453A1 (en) | 2016-02-29 | 2017-09-08 | Regeneron Pharmaceuticals, Inc. | Rodents having a humanized tmprss gene |
| US10912287B2 (en) | 2016-06-28 | 2021-02-09 | Biocytogen Pharmaceuticals (Beijing) Co., Ltd | Genetically modified mice expressing humanized PD-1 |
| DK3507373T5 (da) | 2016-08-31 | 2024-09-02 | Biocytogen Pharmaceuticals Beijing Co Ltd | Genetisk modificeret ikke-menneskeligt dyr med human eller kimær pd-l1 |
| CN107815467B (zh) | 2016-08-31 | 2021-03-16 | 百奥赛图(北京)医药科技股份有限公司 | 人源化基因改造动物模型的制备方法及应用 |
| WO2018041120A1 (en) | 2016-08-31 | 2018-03-08 | Beijing Biocytogen Co., Ltd | Genetically modified non-human animal with human or chimeric tigit |
| CN107815466B (zh) * | 2016-08-31 | 2020-03-13 | 百奥赛图江苏基因生物技术有限公司 | 人源化基因改造动物模型的制备方法及应用 |
| MA46952A (fr) | 2016-12-01 | 2019-10-09 | Regeneron Pharma | Anticorps anti-pd-l1 radiomarqués pour imagerie immuno-pet |
| WO2019072241A1 (en) | 2017-10-13 | 2019-04-18 | Beijing Biocytogen Co., Ltd | NON-HUMAN ANIMAL GENETICALLY MODIFIED WITH PD-1 HUMAN OR CHIMERIC |
| CN109666701B (zh) * | 2017-10-13 | 2021-08-24 | 百奥赛图(北京)医药科技股份有限公司 | 一种pd-1基因修饰人源化动物模型的构建方法及其应用 |
| SG11202002456WA (en) | 2017-11-30 | 2020-04-29 | Regeneron Pharma | Non-human animals comprising a humanized trkb locus |
| WO2019114768A1 (en) | 2017-12-12 | 2019-06-20 | Biocytogen Jiangsu Co., Ltd. | GENETICALLY MODIFIED NON-HUMAN ANIMAL WITH HUMAN OR CHIMERIC CD3e |
| KR20250121150A (ko) | 2018-03-26 | 2025-08-11 | 리제너론 파마슈티칼스 인코포레이티드 | 치료제를 시험하기 위한 인간화된 설치류 |
| AU2019308205B2 (en) | 2018-07-16 | 2025-11-06 | Regeneron Pharmaceuticals, Inc. | Non-human animal models of DITRA disease and uses thereof |
| CN110846321B (zh) * | 2018-08-21 | 2021-11-19 | 中国科学院动物研究所 | 一种突变基因及其用于构建斑色鱼鳞癣小型猪模型的用途 |
| WO2020081585A1 (en) * | 2018-10-15 | 2020-04-23 | The Brigham And Women's Hospital, Inc. | The long non-coding rna inca1 and homo sapiens heterogeneous nuclear ribonucleoprotein h1 (hnrnph1) as therapeutic targets for immunotherapy |
| CN109452229B (zh) * | 2018-11-19 | 2021-10-22 | 百奥赛图(北京)医药科技股份有限公司 | 狗源化pd-1基因改造动物模型的制备方法及应用 |
| CN109979539B (zh) * | 2019-04-10 | 2020-10-02 | 电子科技大学 | 基因序列优化方法、装置及数据处理终端 |
| EP4294180A4 (en) * | 2021-02-19 | 2025-02-12 | Biocytogen Pharmaceuticals (Beijing) Co., Ltd. | Genetically modified non-human animal with human or chimeric cd3 genes |
| CN112999368A (zh) * | 2021-04-09 | 2021-06-22 | 广东药康生物科技有限公司 | 人源化模型进行药效评价方法的建立 |
Family Cites Families (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5670356A (en) | 1994-12-12 | 1997-09-23 | Promega Corporation | Modified luciferase |
| US6485964B1 (en) * | 1995-03-20 | 2002-11-26 | Arris Pharmaceutical Corporation | Transgenic mammals lacking expression of erythropoietin or of erythropoietin receptor, transgenic mammals expressing chimeric erythropoietin receptors, constructs for producing the transgenic mammals and uses therefor |
| GB9517779D0 (en) | 1995-08-31 | 1995-11-01 | Roslin Inst Edinburgh | Biological manipulation |
| GB9517780D0 (en) | 1995-08-31 | 1995-11-01 | Roslin Inst Edinburgh | Biological manipulation |
| US5874304A (en) | 1996-01-18 | 1999-02-23 | University Of Florida Research Foundation, Inc. | Humanized green fluorescent protein genes and methods |
| AU2001273096B8 (en) | 2000-06-28 | 2005-10-13 | Dana-Farber Cancer Institute, Inc. | PD-L2 molecules: novel PD-1 ligands and uses therefor |
| US6586251B2 (en) | 2000-10-31 | 2003-07-01 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US7794710B2 (en) | 2001-04-20 | 2010-09-14 | Mayo Foundation For Medical Education And Research | Methods of enhancing T cell responsiveness |
| DE10211088A1 (de) * | 2002-03-13 | 2003-09-25 | Ugur Sahin | Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung |
| EP2206517B1 (en) | 2002-07-03 | 2023-08-02 | Ono Pharmaceutical Co., Ltd. | Immunopotentiating compositions comprising anti-PD-L1 antibodies |
| WO2004060053A2 (en) * | 2002-12-16 | 2004-07-22 | Genentech, Inc. | Transgenic mice expressing human cd20 |
| JP4511943B2 (ja) | 2002-12-23 | 2010-07-28 | ワイス エルエルシー | Ｐｄ−１に対する抗体およびその使用 |
| EP1701611B1 (en) | 2003-12-24 | 2011-05-18 | G2 Inflammation Pty Ltd | Transgenic non-human mammal comprising a polynucleotide encoding human or humanized c5ar |
| ES2364335T3 (es) | 2003-12-24 | 2011-08-31 | G2 Inflammation Pty Ltd | Mamífero no humano transgénico que comprende un polinucleótido que codifica el c5ar humano o humanizado. |
| MX2007004176A (es) | 2004-10-06 | 2007-06-15 | Mayo Foundation | B7-h1 y metodos de diagnosis, prognosis, y tratamiento de cancer. |
| DK1802193T3 (da) | 2004-10-19 | 2014-06-10 | Regeneron Pharma | Fremgangsmåde til frembringelse af en homozygot mus til genetisk modifikation |
| CN104356236B (zh) * | 2005-07-01 | 2020-07-03 | E.R.施贵宝&圣斯有限责任公司 | 抗程序性死亡配体1(pd-l1)的人单克隆抗体 |
| JP5093097B2 (ja) | 2006-03-03 | 2012-12-05 | 小野薬品工業株式会社 | 細胞表面機能分子の細胞外領域多量体 |
| CA2998281C (en) | 2008-09-26 | 2022-08-16 | Dana-Farber Cancer Institute, Inc. | Human anti-pd-1 antobodies and uses therefor |
| KR101361416B1 (ko) | 2008-10-08 | 2014-02-21 | 인트렉손 코포레이션 | 다수의 면역조절자를 발현하는 조작된 세포 및 그 용도 |
| US20110314563A1 (en) * | 2008-12-18 | 2011-12-22 | Kingdon Craig R | Antibody production |
| ES2629337T3 (es) | 2009-02-09 | 2017-08-08 | Inserm - Institut National De La Santé Et De La Recherche Médicale | Anticuerpos contra PD-1 y anticuerpos contra PD-L1 y usos de los mismos |
| RU2425880C2 (ru) * | 2009-07-30 | 2011-08-10 | Учреждение Российской академии наук Институт общей генетики им. Н.И. Вавилова РАН | Способ получения трансгенных мышей |
| US8518392B2 (en) | 2009-08-14 | 2013-08-27 | Regeneron Pharmaceuticals, Inc. | Promoter-regulated differentiation-dependent self-deleting cassette |
| AU2010286516B2 (en) * | 2009-08-28 | 2016-10-06 | Regeneron Pharmaceuticals, Inc. | Antikine antibodies that bind to multiple CC chemokines |
| AU2010303737B2 (en) | 2009-10-06 | 2014-05-29 | Institute For Research In Biomedicine (Irb) | Genetically modified mice and engraftment |
| WO2011060357A2 (en) | 2009-11-16 | 2011-05-19 | The Ohio State University | Engineered xenogeneic cells for repair of biological tissue |
| CA2778714C (en) | 2009-11-24 | 2018-02-27 | Medimmune Limited | Targeted binding agents against b7-h1 |
| NO2516457T3 (enExample) * | 2009-12-21 | 2018-08-11 | ||
| US8507663B2 (en) * | 2010-04-06 | 2013-08-13 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of CD274/PD-L1 gene |
| KR102256316B1 (ko) | 2011-02-15 | 2021-05-28 | 리제너론 파마슈티칼스 인코포레이티드 | 인간화된 ｍ－ｃｓｆ 마우스 |
| RS56656B1 (sr) | 2011-10-28 | 2018-03-30 | Regeneron Pharma | Miševi sa genetski modifikovanim glavnim kompleksom gena tkivne podudarnosti |
| RU2634417C2 (ru) | 2011-10-28 | 2017-10-26 | Регенерон Фармасьютикалс, Инк. | Гуманизированные il-6 и рецептор il-6 |
| CA2852962C (en) | 2011-10-28 | 2022-05-03 | Regeneron Pharmaceuticals, Inc. | Genetically modified mice expressing chimeric major histocompatibility complex (mhc) ii molecules |
| WO2013078230A1 (en) | 2011-11-23 | 2013-05-30 | The Trustees Of The University Of Pennsylvania | Use of pdl1 expressing cells to convert t cells into regulatory t cells |
| ES2808152T3 (es) | 2011-11-28 | 2021-02-25 | Merck Patent Gmbh | Anticuerpos anti-PD-L1 y usos de los mismos |
| WO2014022758A1 (en) | 2012-08-03 | 2014-02-06 | Dana-Farber Cancer Institute, Inc. | Single agent anti-pd-l1 and pd-l2 dual binding antibodies and methods of use |
| US20140047572A1 (en) * | 2012-08-13 | 2014-02-13 | University Of Rochester | Thrombopoietin mimetics for the treatment of radiation or chemical induced bone marrow injury |
| WO2014031610A1 (en) * | 2012-08-21 | 2014-02-27 | Sanofi | Methods for treating or preventing asthma by administering an il-4r antagonist |
| DK2892330T3 (da) | 2012-09-07 | 2023-01-30 | Univ Yale | Genetisk modificeret mus og fremgangsmåder til anvendelse deraf |
| EP3939423B1 (en) | 2012-11-05 | 2024-03-06 | Regeneron Pharmaceuticals, Inc. | Genetically modified non-human animals and methods of use thereof |
| EP2948475A2 (en) | 2013-01-23 | 2015-12-02 | AbbVie Inc. | Methods and compositions for modulating an immune response |
| PT2958938T (pt) * | 2013-02-20 | 2019-07-23 | Regeneron Pharma | Ratinhos que expressam correcetores de células t humanizados |
| AU2014218931C1 (en) | 2013-02-20 | 2020-05-14 | Regeneron Pharmaceuticals, Inc. | Genetic modification of rats |
| CN110192541B (zh) | 2013-02-22 | 2022-02-18 | 瑞泽恩制药公司 | 表达人源化主要组织相容性复合物的小鼠 |
| US20150342163A1 (en) | 2013-02-22 | 2015-12-03 | Regeneron Pharmaceuticals, Inc. | Genetically modified major histocompatibility complex mice |
| HRP20181648T1 (hr) | 2013-04-16 | 2019-01-25 | Regeneron Pharmaceuticals, Inc. | Ciljana modifikacija genoma štakora |
| CN103242448B (zh) * | 2013-05-27 | 2015-01-14 | 郑州大学 | 一种全人源化抗pd-1单克隆抗体及其制备方法和应用 |
| EP3293275B1 (en) | 2013-06-06 | 2021-08-04 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for identification, assessment prevention, and treatment of cancer using pd-l1 isoforms |
| SMT202300287T1 (it) | 2013-09-23 | 2023-11-13 | Regeneron Pharma | Animali non umani aventi un gene umanizzato della proteina regolatrice del segnale |
| SG11201603360QA (en) | 2013-11-19 | 2016-05-30 | Regeneron Pharma | Non-human animals having a humanized b-cell activating factor gene |
| TWI680138B (zh) * | 2014-01-23 | 2019-12-21 | 美商再生元醫藥公司 | 抗ｐｄ-ｌ１之人類抗體 |
| HUE051088T2 (hu) | 2014-04-08 | 2021-03-01 | Regeneron Pharma | Humanizált FC-gamma receptorokkal rendelkezõ nem humán élõlények |
| NO2785538T3 (enExample) | 2014-05-07 | 2018-08-04 | ||
| IL312888A (en) | 2014-05-19 | 2024-07-01 | Regeneron Pharma | Genetically modified non-human animals expressing human epo |
| SG10201811116UA (en) * | 2014-06-19 | 2019-01-30 | Regeneron Pharma | Non-human animals having a humanized programmed cell death 1 gene |
| SI3689140T1 (sl) | 2014-11-24 | 2022-10-28 | Regeneron Pharmaceuticals, Inc. | Nehumane živali, ki izražajo humaniziran CD3 kompleks |
| PL3086637T3 (pl) | 2014-12-05 | 2019-09-30 | Regeneron Pharmaceuticals, Inc. | Zwierzęta nie będące człowiekiem mające humanizowany gen kompleksu różnicowania 47 |
| LT3230320T (lt) * | 2014-12-09 | 2021-01-11 | Regeneron Pharmaceuticals, Inc. | Gyvūnai, išskyrus žmogų, turintys humanizuotą diferenciacijos klasterio 274 geną |
| WO2017087780A1 (en) | 2015-11-20 | 2017-05-26 | Regeneron Pharmaceuticals, Inc. | Non-human animals having a humanized lymphocyte-activation gene 3 |
| DK3507373T5 (da) | 2016-08-31 | 2024-09-02 | Biocytogen Pharmaceuticals Beijing Co Ltd | Genetisk modificeret ikke-menneskeligt dyr med human eller kimær pd-l1 |
-
2015
- 2015-12-09 LT LTEP15816631.4T patent/LT3230320T/lt unknown
- 2015-12-09 EP EP20194168.9A patent/EP3808775B1/en active Active
- 2015-12-09 HR HRP20240855TT patent/HRP20240855T1/hr unknown
- 2015-12-09 CN CN201580067025.6A patent/CN107257624B/zh active Active
- 2015-12-09 KR KR1020177016266A patent/KR102316842B1/ko active Active
- 2015-12-09 NZ NZ731954A patent/NZ731954A/en unknown
- 2015-12-09 ES ES20194168T patent/ES2982515T3/es active Active
- 2015-12-09 IL IL282649A patent/IL282649B/en unknown
- 2015-12-09 SM SM20240313T patent/SMT202400313T1/it unknown
- 2015-12-09 BR BR112017011982A patent/BR112017011982A2/pt not_active Application Discontinuation
- 2015-12-09 CA CA2968675A patent/CA2968675C/en active Active
- 2015-12-09 ES ES15816631T patent/ES2841353T3/es active Active
- 2015-12-09 JP JP2017530591A patent/JP2018500896A/ja not_active Withdrawn
- 2015-12-09 HR HRP20202034TT patent/HRP20202034T1/hr unknown
- 2015-12-09 US US14/963,402 patent/US9913461B2/en active Active
- 2015-12-09 PT PT158166314T patent/PT3230320T/pt unknown
- 2015-12-09 KR KR1020217033684A patent/KR102457921B1/ko active Active
- 2015-12-09 SG SG11201703931QA patent/SG11201703931QA/en unknown
- 2015-12-09 PL PL20194168.9T patent/PL3808775T3/pl unknown
- 2015-12-09 SG SG10202100792XA patent/SG10202100792XA/en unknown
- 2015-12-09 FI FIEP20194168.9T patent/FI3808775T3/fi active
- 2015-12-09 MX MX2017007636A patent/MX2017007636A/es unknown
- 2015-12-09 DK DK15816631.4T patent/DK3230320T3/da active
- 2015-12-09 EP EP15816631.4A patent/EP3230320B1/en active Active
- 2015-12-09 DK DK20194168.9T patent/DK3808775T3/da active
- 2015-12-09 HU HUE15816631A patent/HUE052606T2/hu unknown
- 2015-12-09 PT PT201941689T patent/PT3808775T/pt unknown
- 2015-12-09 SM SM20210148T patent/SMT202100148T1/it unknown
- 2015-12-09 WO PCT/US2015/064626 patent/WO2016094481A1/en not_active Ceased
- 2015-12-09 LT LTEP20194168.9T patent/LT3808775T/lt unknown
- 2015-12-09 RS RS20240717A patent/RS65664B1/sr unknown
- 2015-12-09 SI SI201532021T patent/SI3808775T1/sl unknown
- 2015-12-09 EP EP24167621.2A patent/EP4399969A3/en active Pending
- 2015-12-09 SI SI201531463T patent/SI3230320T1/sl unknown
- 2015-12-09 AU AU2015360667A patent/AU2015360667B2/en active Active
- 2015-12-09 RU RU2017123754A patent/RU2711729C2/ru active
- 2015-12-09 HU HUE20194168A patent/HUE067123T2/hu unknown
- 2015-12-09 NZ NZ770783A patent/NZ770783A/en unknown
- 2015-12-09 RS RS20201547A patent/RS61218B1/sr unknown
- 2015-12-09 CN CN202110688677.9A patent/CN113412818B/zh active Active
-
2017
- 2017-05-11 ZA ZA2017/03263A patent/ZA201703263B/en unknown
- 2017-06-06 IL IL252695A patent/IL252695B/en active IP Right Grant
-
2018
- 2018-01-30 US US15/883,477 patent/US10881086B2/en active Active
-
2020
- 2020-07-06 IL IL275864A patent/IL275864B/en active IP Right Grant
- 2020-10-05 JP JP2020168478A patent/JP7145920B2/ja active Active
- 2020-12-03 US US17/110,868 patent/US12089575B2/en active Active
- 2020-12-23 CY CY20201101215T patent/CY1123723T1/el unknown
-
2021
- 2021-12-16 AU AU2021286369A patent/AU2021286369B2/en active Active
-
2022
- 2022-09-20 JP JP2022148949A patent/JP7488861B2/ja active Active
-
2024
- 2024-08-15 US US18/805,786 patent/US20240389563A1/en active Pending
-
2025
- 2025-06-24 AU AU2025204751A patent/AU2025204751A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ731954A (en) | Non-human animals having a humanized cluster of differentiation 274 gene | |
| SG10201811116UA (en) | Non-human animals having a humanized programmed cell death 1 gene | |
| NZ769992A (en) | Non-human animals having a humanized cluster of differentiation 47 gene | |
| MX2017006802A (es) | Animales no humanos que expresan el complejo cd3 humanizado. | |
| WO2014130671A8 (en) | Mice expressing humanized t-cell co-receptors | |
| MX368931B (es) | Animales no humanos que tienen un gen de proteina reguladora de señal humanizado. | |
| NZ702943A (en) | Humanized il-7 rodents | |
| MX2016014504A (es) | Animales c5 y c3 humanizados. | |
| MX2020003491A (es) | Roedores humanizados que expresan cadenas pesadas que contienen dominios vl. | |
| MX2019002482A (es) | Animales geneticamente modificados y metodo para su obtencion. | |
| BR112018010158A2 (pt) | roedor, polipeptídeo lag-3 humanizado, célula ou tecido, célula-tronco embrionária e embrião de roedor, métodos para produzir um roedor, para avaliar a eficácia antitumoral e as propriedades farmacocinéticas de uma droga | |
| SG10201900003WA (en) | Non-human animals having a humanized b-cell activating factor gene | |
| WO2016106159A8 (en) | Anti-pd-1 antibodies | |
| EA201992358A1 (ru) | Тканеселективная экспрессия трансгена | |
| SG10201811701YA (en) | Non-human animals having a humanized a proliferation-inducing ligand gene | |
| MX2016004781A (es) | Il-15 humanizada en animales. | |
| MX389758B (es) | Ratones con genes insertados de sirpa-il15 humanizadas y métodos para usarlos | |
| NZ734256A (en) | Use of plinabulin in combination with immune checkpoint inhibitors | |
| MX2021014818A (es) | Anticuerpos monoclonales anti-cd303. | |
| MX355726B (es) | Ratones transgenicos que expresan moleculas quimericas del complejo mayor de histocompatibilidad (cmh) clase ii. | |
| MX2016013241A (es) | Animales no humanos que tienen receptores fc gamma humanizados. | |
| MX2014012977A (es) | Anticuerpos anti-cd22. | |
| IL272911A (en) | Antibodies to programmed cell death protein 1 (PD-1) | |
| EP4249507A3 (en) | Transgenic mice expressing chimeric major histocompatibility complex (mhc) class ii molecules | |
| MX2018009513A (es) | Animales no humanos que tienen un gen angptl8 modificado genéticamente. |